Tesamorelin (brand name Egrifta) is FDA-approved for reduction of visceral adiposity in HIV patients, produces similar effects to sermorelin including increased deep sleep, is more long-lasting than sermorelin, and is typically taken 3 times per week rather than 5 times per week.

factualpending

Speaker

Andrew Huberman

Evidence Quote

“tesamorelin...Egrifta...FDA approved drug for the reduction of visceral adiposity...more long-lasting than sermorelin...three times per week, not five times per week”

Source

Benefits & Risks of Peptide Therapeutics for Physical & Mental Health— Andrew Huberman
Created: 8/11/2026, 6:26:50 AM

Your notes

Loading notes...